Three insights:
1. A total of six patients were treated with DiscSeal, a viscous material injected percutaneously into the intervertebral diseased disc of patients under local anesthesia.
2. The product was administered to patients with low back pain caused by discogenic disease and who have not been sufficiently treated by first-line medical therapy.
3. The study aims to evaluate DiscSeal’s safety and efficacy in reducing levels of pain from the patients’ pre-treatment pain levels over a six-month period.
More articles on biologics:
Stryker ranks No. 8 in Fortune’s 100 best workplaces
Wuhan neurosurgeon, hospital director dies from coronavirus, death toll rises to 1,800+
Medtronic reports spine revenue up 3%, hurt by low BMP sales: 7 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
